Candel Therapeutics (CADL) Interest Expenses (2020 - 2025)
Candel Therapeutics (CADL) posted Interest Expenses of $577000.0 for Q4 2025, down 94.94% sequentially from $11.4 million in Q3 2025, and down 8.12% YoY from $628000.0 in Q4 2024.
Candel Therapeutics (CADL) Interest Expenses (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Interest Expenses for 6 years, with the latest figure at $577000.0 in Q4 2025.
- Quarterly Interest Expenses fell 8.12% year-over-year to $577000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.1 million (down 4.24% YoY) and the FY2025 annual result came in at $65.3 million, up 136.49% from the prior year.
- Interest Expenses retreated to $577000.0 in Q4 2025 per CADL's latest filing, from $11.4 million in the prior quarter.
- Over five years, Interest Expenses peaked at $29.2 million in Q1 2022 and troughed at $226000.0 in Q4 2023.
- A 5-year average of $8.0 million and a median of $669000.0 in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses sank 97.91% in 2023, then jumped 2933.78% in 2024.
- Over 5 years, Interest Expenses stood at $18.5 million in 2021, then slumped by 97.3% to $500000.0 in 2022, then plunged by 54.8% to $226000.0 in 2023, then soared by 177.88% to $628000.0 in 2024, then retreated by 8.12% to $577000.0 in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $577000.0, $11.4 million, and $11.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | 577,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 577,000.00 |
| Dec 31, 2025 | 577,000.00 |
| Sep 30, 2025 | 11.40 Mn |
| Sep 30, 2025 | 11.40 Mn |
| Jun 30, 2025 | 11.27 Mn |
| Jun 30, 2025 | 11.27 Mn |
| Mar 31, 2025 | 13.85 Mn |
| Mar 31, 2025 | 13.85 Mn |
| Dec 31, 2024 | 628,000.00 |
| Dec 31, 2024 | 628,000.00 |
| Sep 30, 2024 | 20.30 Mn |
| Sep 30, 2024 | 20.30 Mn |
| Jun 30, 2024 | 17.39 Mn |
| Jun 30, 2024 | 17.39 Mn |
| Mar 31, 2024 | 646,000.00 |
| Mar 31, 2024 | 646,000.00 |
| Dec 31, 2023 | 226,000.00 |
| Dec 31, 2023 | 226,000.00 |
| Sep 30, 2023 | 669,000.00 |
| Sep 30, 2023 | 669,000.00 |